CCL4 / MIP-1-beta, N-GST, recombinant protein

Description of CCL4 / MIP-1-beta, N-GST, recombinant protein

Introduction:

CCL4/MIP-1-beta, N-GST is a recombinant protein that has gained significant attention in the field of drug development due to its potential as a drug target. This protein is a chemokine, which plays a crucial role in the immune response and has been associated with various diseases. In this article, we will delve into the structure, activity, and potential applications of CCL4/MIP-1-beta, N-GST recombinant protein.

Structure of CCL4/MIP-1-beta, N-GST Recombinant Protein:

CCL4/MIP-1-beta, N-GST is a chemokine that belongs to the CC chemokine family. It is a small protein with a molecular weight of approximately 8 kDa and is composed of 69 amino acids. The protein has a highly conserved structure, with four cysteine residues that form two disulfide bonds, giving it a characteristic “”CC”” motif. This motif is crucial for its biological activity as it allows the protein to interact with specific receptors on the cell surface.

Activity of CCL4/MIP-1-beta, N-GST Recombinant Protein:

CCL4/MIP-1-beta, N-GST plays a vital role in the immune response by regulating the recruitment and activation of immune cells. It acts as a chemoattractant, guiding immune cells to the site of inflammation or infection. This protein is primarily produced by activated T cells, macrophages, and dendritic cells in response to various stimuli, such as pathogens or cytokines.

CCL4/MIP-1-beta, N-GST exerts its biological effects by binding to its receptors, CCR1, CCR5, and CCR8, which are expressed on the surface of immune cells. This binding triggers a series of signaling events that lead to the activation of immune cells and their migration to the site of inflammation. Additionally, CCL4/MIP-1-beta, N-GST has been shown to have antimicrobial properties, suggesting a potential role in the defense against infections.

Applications:

Due to its crucial role in the immune response, CCL4/MIP-1-beta, N-GST has been implicated in various diseases, making it a potential drug target. For instance, in inflammatory diseases such as rheumatoid arthritis and multiple sclerosis, there is an overproduction of CCL4/MIP-1-beta, N-GST, leading to excessive immune cell recruitment and tissue damage. Therefore, targeting this protein could help in controlling the inflammatory response and reducing disease severity.

Moreover, CCL4/MIP-1-beta, N-GST has been linked to cancer progression and metastasis. It has been shown to promote the migration and invasion of cancer cells, making it a potential target for cancer therapy. In addition, CCL4/MIP-1-beta, N-GST has been found to play a role in viral infections, such as HIV and hepatitis C. Therefore, targeting this protein could potentially help in controlling viral replication and spread.

Conclusion:

In summary, the structure and activity of CCL4/MIP-1-beta, N-GST recombinant protein make it a promising drug target for various diseases. Its role in the immune response and its involvement in various diseases make it a potential target for drug development. Further research on this protein and its receptors could lead to the development of novel therapies for inflammatory diseases, cancer, and viral infections.